Linked Data API
Show Search Form
Search Results
 |
human indexable |  |
 |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
published | |
|
||||||||
|
registered interest |  |
|
||||||||
|
answer date |   |
|||||||||
|
date |  |
|||||||||
|
date tabled | |
|||||||||
|
ddp created |  |
|||||||||
|
answering body |
|
|||||||||
|
question status | Tabled | |
||||||||
|
answering dept id | 17 | |
||||||||
|
answering dept short name | Health and Social Care | |
||||||||
|
answering dept sort name | Health and Social Care | |
||||||||
|
ddp modified |
|
|||||||||
 |
hansard heading | Leukaemia: Ibrutinib | |
||||||||
|
house id | 2 | |
||||||||
|
identifier | HL8564 | |
||||||||
|
legislature |
|
|||||||||
|
parliament number | 57 | |
||||||||
|
question first answered |
|
|||||||||
|
question text | To ask Her Majesty's Government (1) what evidence NHS England considered, (2) which clinicians it consulted, and (3) which patient groups it consulted when deciding that ibrutinib should not be prescribed to people with chronic lymphocytic leukaemia who have been in remission for more than three years. | |
||||||||
|
session |
|
|||||||||
|
session number | 1 | |
||||||||
|
tabling member printed |
|
|||||||||
|
title | House of Lords Tabled Parliamentary Question 2017/19 HL8564 | |
||||||||
|
type |
|
|||||||||
|
uin | HL8564 | |
||||||||
|
version | 1 | |
||||||||
|
written parliamentary question type | Ordinary | |
||||||||
|
answer |
|
|||||||||
|
creator |
|
|||||||||
|
publisher | 25277 | |||||||||
|
tabling member |
|
|||||||||